drugset / Trial / NCT01794845
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
Timeline
- Start
- 2013-06-03
- Primary completion
- 2016-06-07
- Completion
- 2016-06-07
Outcome
Outcome not reported
Stopped: “Early termination due to lack of efficacy (overall response)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 20 mg/m2 | Intravenous |